"Splendor on the grass....
Tanglewood was the place to be Saturday, too, as the BSO opened its summer season with a lavish Grecian feast that gave the fabulous folk an excuse to party on the wet grass, replete with grilled Maine lobster, figs, dates, nuts, and Baklava on gold-rimmed plates. There were a few other familiar faces among the party people, including James and Kim Taylor, Governor Deval Patrick and wife Diane, who gave up their seats in the shed to listen from the lawn, "Indiana Jones" actress and knitwear designer Karen Allen, former Senate prez Billy Bulger, who was seated next to Berkshire benefactors Jane and Jack Fitzpatrick, BSO chairman Edward Linde and wife Joyce, and Lenox Representative Smitty Pignatelli."
(Editor's note: I saw Karen Allen do a Berkshire Co. play over the summer many years ago)
Yup, while schools are closing and bridges falling apart, the guv is PARTYING in STYLE!!!!!
Of course, it is all right to toss money at rich Hollywood folk or corporate and lottery favorites, as well as Wall Street.
Here's the latest transgression:
"Despite downturn, biotechs are still attracting investor attention; Agios of Boston raises $33m in venture capital" By Todd Wallack, Globe Staff | July 7, 2008
The stock market is down. Initial public stock offerings are rare. But local biotech companies keep landing impressive sums to develop cutting-edge medical treatments.
Still, like many biotech start-ups, the company is years away from developing drugs that are ready to be tested in humans.
Agios is temporarily operating out of Third Rock's offices in Boston, but is looking for office and lab space in Cambridge. Starr said it hopes to have 25 employees within a year and 35 within two. He also is recruiting a management team, including a permanent chief executive.
So far this year, there haven't been any venture-backed IPOs from Massachusetts, because of the turmoil on Wall Street. But major drug companies are continuing to gobble up biotech companies, giving venture investors another way to cash out of their investment. For instance, GlaxoSmithKline PLC paid $720 million for Sirtris Pharmaceuticals Inc., a Cambridge company trying to combat aging-related diseases. And Takeda Pharmaceutical paid an eye-popping $8.8 billion for Millennium, which owns a fast-growing cancer drug, Velcade.
--MORE--"
Yeah, about those cancer drugs: The Cancer Cash Cow
